App aims to reduce eye injection visits for macular degeneration
NCT ID NCT07340372
Summary
This study is testing whether a smartphone app can help people with wet age-related macular degeneration (AMD) safely go longer between their regular eye injections. 80 participants already receiving Aflibercept 8 mg injections will use the app at home to monitor their vision for a year or two. The goal is to see if home monitoring provides enough reassurance for doctors to extend treatment intervals, potentially reducing clinic visits while maintaining good vision.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXUDATIVE AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Espaço Médico de Coimbra, Lda.
Coimbra, Portugal
Contact
-
Instituto Português de Microcirurgia Ocular, Lda.
Lisbon, Portugal
Contact
-
Unidade Local de Saúde Loures-Odivelas
Loures, Portugal
Contact
-
Unidade Local de Saúde de Coimbra, E.P.E.
Coimbra, Portugal
Contact
-
Unidade Local de Saúde de Leiria, E.P.E.
Leiria, Portugal
Contact
-
Unidade Local de Saúde de Lisboa Ocidental - Hospital de Egas Moniz
Lisbon, Portugal
Contact
-
Unidade Local de Saúde de Santo António, E.P.E.
Porto, Portugal
Contact
-
Unidade Local de Saúde de São João, E.P.E.
Porto, Portugal
Contact
Conditions
Explore the condition pages connected to this study.